Literature DB >> 20575712

Carraguard acceptability among men and women in a couples study in Thailand.

Sarah Martin1, Kelly Blanchard, Chomnad Manopaiboon, Supaporn Chaikummao, Kate Schaffer, Barbara Friedland, Peter H Kilmarx.   

Abstract

OBJECTIVE: The aim of this study is to evaluate the use and acceptability of Carraguard among men and women enrolled as couples in a microbicide trial.
MATERIALS AND METHODS: Focus groups were conducted with participants in a 6-month randomized, placebo-controlled trial that enrolled sexually active, low-risk couples in Thailand. Participants were blinded as to which gel they had received at the time of the discussions.
RESULTS: Most men and women liked the gel and found it acceptable. The majority of men and women thought that using the gel increased sexual pleasure, although participants disagreed about whether using the gel increased sexual frequency. Drawbacks of gel use included that it was too wet or messy, and nearly all respondents thought that the applicator was too hard. Most men and women questioned the utility of using the gel among married couples since gel use was tied to perception of HIV/STI risk. However, those who perceived themselves to be at risk expressed interest in using the product as an alternative to condoms. Many women were particularly interested in a product that also had contraceptive properties. Gel use also raised issues of trust and fidelity among couples and questions about men's ability to detect women's use of the product.
CONCLUSION: Men and women in this study found the gel acceptable and thought that it should be made available if it is found to be safe and effective. Strategies for marketing a potential microbicide product must take the target population into consideration. For married couples, key considerations may be partner dynamics and trust issues, whereas messages focusing on sexual pleasure or disease prevention may resonate more strongly with sex workers or other populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20575712     DOI: 10.1089/jwh.2009.1362

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  13 in total

1.  Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.

Authors:  José A Fernández-Romero; Ciby J Abraham; Aixa Rodriguez; Larisa Kizima; Ninochka Jean-Pierre; Radhika Menon; Othell Begay; Samantha Seidor; Brian E Ford; Pedro I Gil; Jennifer Peters; David Katz; Melissa Robbiani; Thomas M Zydowsky
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 2.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

Review 3.  The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept.

Authors:  Jenny A Higgins; Nicole K Smith
Journal:  J Sex Res       Date:  2016-03-08

4.  In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.

Authors:  Aixa Rodríguez; Kyle Kleinbeck; Olga Mizenina; Larisa Kizima; Keith Levendosky; Ninochka Jean-Pierre; Guillermo Villegas; Brian E Ford; Michael L Cooney; Natalia Teleshova; Melissa Robbiani; Betsy C Herold; Thomas Zydowsky; José A Fernández Romero
Journal:  Antiviral Res       Date:  2014-06-05       Impact factor: 5.970

5.  The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques.

Authors:  R Singer; N Derby; A Rodriguez; L Kizima; J Kenney; M Aravantinou; A Chudolij; A Gettie; J Blanchard; J D Lifson; M Piatak; J A Fernández-Romero; T M Zydowsky; M Robbiani
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

6.  The Promise of Antiretrovirals for HIV Prevention.

Authors:  Charlene Flash; Douglas Krakower; Kenneth H Mayer
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

7.  A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo.

Authors:  Jessica Kenney; Aixa Rodríguez; Larisa Kizima; Samantha Seidor; Radhika Menon; Ninochka Jean-Pierre; Pavel Pugach; Keith Levendosky; Nina Derby; Agegnehu Gettie; James Blanchard; Michael Piatak; Jeffrey D Lifson; Gabriela Paglini; Thomas M Zydowsky; Melissa Robbiani; José A Fernández Romero
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

8.  Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity.

Authors:  Charlene S Dezzutti; Elizabeth R Brown; Bernard Moncla; Julie Russo; Marilyn Cost; Lin Wang; Kevin Uranker; Ratiya P Kunjara Na Ayudhya; Kara Pryke; Jim Pickett; Marc-André Leblanc; Lisa C Rohan
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques.

Authors:  Jessica Kenney; Meropi Aravantinou; Rachel Singer; Mayla Hsu; Aixa Rodriguez; Larisa Kizima; Ciby J Abraham; Radhika Menon; Samantha Seidor; Anne Chudolij; Agegnehu Gettie; James Blanchard; Jeffrey D Lifson; Michael Piatak; Jose A Fernández-Romero; Thomas M Zydowsky; Melissa Robbiani
Journal:  PLoS One       Date:  2011-01-05       Impact factor: 3.240

10.  A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV.

Authors:  Larisa Kizima; Aixa Rodríguez; Jessica Kenney; Nina Derby; Olga Mizenina; Radhika Menon; Samantha Seidor; Shimin Zhang; Keith Levendosky; Ninochka Jean-Pierre; Pavel Pugach; Guillermo Villegas; Brian E Ford; Agegnehu Gettie; James Blanchard; Michael Piatak; Jeffrey D Lifson; Gabriela Paglini; Natalia Teleshova; Thomas M Zydowsky; Melissa Robbiani; José A Fernández-Romero
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.